Literature DB >> 31762820

CircRNAs and its relationship with gastric cancer.

Xinxin Fang1,2, Jing Wen1,2, Mingjun Sun2,3, Yuan Yuan1,3, Qian Xu1,3.   

Abstract

Circular RNAs (circRNAs), as a type of tissue specific RNA with more stable structure than linear RNAs, was poorly understood on its correlation with gastric cancer (GC). In this review, we outline the synthesis and characteristics of circRNAs and generalize their categories and functions. Through comprehensive analysis of the reported results, we find that circRNAs not only participate in the regulation of gastric cancer (GC) cell biological behaviors, such as proliferation, invasion, migration and epithelial mesenchymal transition (EMT), but also are related to the clinicopathological features of GC such as tumor differentiation, TNM stage and metastasis, etc. According to the present screening and verification results, circRNAs are suggested to be used as biomarkers for the early diagnosis and prognosis prediction of GC, and those circRNAs involved in the genesis and development of GC have the potential as novel targets for the individualized treatment of GC. © The author(s).

Entities:  

Keywords:  cell biological behaviors; circRNA; diagnosis; gastric cancer; prognosis

Year:  2019        PMID: 31762820      PMCID: PMC6856571          DOI: 10.7150/jca.32927

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


Introduction

Circular RNAs (circRNAs) were first discovered by scientists when using electron microscope to observe RNA virus in the 1970s1. Nevertheless, due to the technique limitations, circRNAs were originally considered as by-products of mRNA error splicing, occupying minimal amount in cells2. With the development and progress of scientific technologies, especially the appearance of high-throughput sequencing and bio-informatics, mounting circRNA families have been found in prokaryotes, animals, plants, and humans3-6. As non-coding RNA (ncRNA) with neither 3'-5'end polarity nor polynucleotide tails, it was revealed in many researches that circRNAs play essential roles in tumorgenesis and development7. Until now, a few of review articles had been previously published to elucidate the potential relationship between circRNAs and cancer. But most of them were tried to study the associated of circRNAs and the overall cancer. Compared to those of previous studies, we focused on the relationship between circRNAs and gastric cancer which is the fifth common cancer and the third major cause of cancer death worldwide 8. We aim to explore the relationships between circRNAs and GC by briefly describing the biological characteristics, process of synthesis and scavenging, classification and function of circRNAs; comprehensively summarizing the correlations of circRNAs with biological behaviors of GC cells and clinicopathological features of GC patients; and systematically reviewing the applications of circRNAs as biomarkers in prediction, diagnosis, treatment and prognosis of GC (Figure 1).
Figure 1

The graphic summary of this review.

Biological characteristics of circRNAs

On account of the unique circular structure, circRNAs vary from linear RNAs in several characteristics, which are the preconditions of being biomarkers for disease. The characteristics of circRNAs are as follow: Ⅰ. Strong stability: CircRNA is a covalently closed loop structure without 3'/5' end polarity and polynucleotide tail. Therefore, circRNA cannot be affected by ribonuclease R and RNA nucleic acid exonuclease7. Ⅱ. Abundant content: Owing to its strong stability and relative long half-life period, circRNA is 10 times richer than corresponding linear RNAs in cells and is also abundant in extracellular fluid3, 5. Thus, the expression levels of circRNAs in tissues at present can be detected by real-time fluorescent quantitative PCR experiment. Besides, owing to the specific and stable characteristics of circRNAs, their expression levels can also be detected in plasma, saliva and urine. Therefore, circRNAs can be regarded as promising biomarkers for diagnosis and prognosis assessment of diseases9-12. Ⅲ. Specific expression: Tissue- or developmental stage- specific expressions of circRNAs can frequently be observed in the same organism, and the specificity also exist among different species3, 13. Hence, circRNA as normal dynamic balanced product of gene and a member of regulatory pathway in cells, participates in the development of diseases and may act as specific target for the disease treatment.

Synthesis and removal of circRNAs

The homeostasis of circRNAs in cells are attributed to their specific biosynthesis and scavenging mechanisms. Firstly, for the coding genes of circRNAs, most of their gene sequences are located in exon regions of host genes, and others are located in introns or intergenic regions3, 5, 14. Some exons can transcribe multiple circRNAs 3, 14. Secondly, regarding the biosynthesis patterns of circRNAs, back-splicing pattern is the most widely recognized one. The majority of circRNAs are synthesized at the post-transcriptional level through pre-mRNA back-splicing 15, 16. During the back-splicing process, the 5' and the 3' end splicing site form a covalent closed ring by 3'-5'phosphodiester bond7, 14. CircRNAs are synthesized by back-splicing at a very slow pace under natural condition, however, the biosynthetic speed can be affected by multiple factors including the competitions of pre-mRNA splicing, the distances between RNA binding protein (RBP) -induced splicing sites, the extension rates of RNA rapid polymerase Ⅱ, the controls of cis-acting elements in vivo and the self positive feedback, etc 15, 17-19. Besides, the known mechanism for circRNAs scavenging is that the intracellular circRNA can be excreted out of cells through the extracellular vesicles (EVs). Then, part of the EVs rupture and release the circRNAs into extracellular fluid; another part are absorbed by other cells along with encapsulated circRNAs20.

Categories and function of circRNAs

Based on the coding genes, tens of thousands of circRNAs are divided into different subtypes, which are as follows. Ⅰ. exon circRNAs (ecircRNAs), generated from exons3. Ⅱ. intron circRNAs (ciRNAs), generated from introns3, 21. Ⅲ. exon and intron circRNAs (EIciRNAs), generated from both exons and introns22. Ⅳ. fusion circRNA (f-circRNAs), generated from cancer-associated chromosomal translocations23. EcircRNAs are enriched in cytoplasm, while ciRNAs and EIciRNAs are distributed in cytoplasm with less amount 3, 21, 24. With in-depth researches, the biological functions of circRNAs gradually emerge and researches revealed that subtypes of circRNAs were not only distinct in cellular localizations, but also in biological functions. Firstly, circRNAs can function as natural sponge of miRNAs. In cytoplasma, ecircRNAs as the sponge of miRNAs, restrain miRNAs functions, thus regulating the expressions of target mRNAs4, 25. In nucleus, ciRNAs may act as the sponge of protein, influencing cell function17, 26. Secondly, ciRNAs and EIciRNAs can activate or positively regulate the transcriptions of parental genes in the nucleus21, 24. Thirdly, as mentioned above, some cells can transport circRNAs out of cells via EVs and then were acquired by other cells through intaking these EVs, which means circRNAs may contribute to the cell communications20. Fourthly, latest research elucidated that intracellular circRNAs can be used as templates for protein translations. Fifthly, in cells, when the circRNAs sequence contains the m6A sequence, translation can be performed and the changes of m6A expression level affect the efficiency of this process27, 28.

Interactive network of circRNAs with other non-coding RNA and proteins

CircRNAs can form regulatory pathways with other biomolecules in cells with miRNAs, siRNAs, lncRNAs and proteins through various different ways. Ⅰ, circRNAs could form a regulatory pathway with the small size non-coding RNA, miRNAs4. Hansen, TB and his team demonstrated that the target sites of miR-7 exist on ciRS-7 and the ciRS-7 can more effectively inhibit miR-7, comparing with traditional anti-miRNA methods4. Deserved to be mentioned, this is the first circRNA-miRNA regulatory pathway be discovered. Subsequently, scientists also revealed this ciRS-7-miR-7 co-expression pathway when they researched other miR-7 related physiological and pathological processes in the human diseases including insulin secretion, tumor, neurodegenerative diseases, intervertebral disc degeneration, systemic lupus erythematosus, etc29-33. Coexpression of ciRS-7-miR-7 was also found in the brains of different animals and plants34-36. Therefore, this circRNA-miRNA regulatory pathway not only extensively exist in nature, but also is a diversified regulatory pathway that regulates many physiological and pathological processes34-36. A miRNA may be controlled by multiple circRNAs, and a circRNA can also suppress the various miRNAs at the same time4, 37-39. CircRNAs can not only inhibit the function of miRNAs through the ceRNAs (competing endogenous RNAs) network mechanism to form regulatory pathways, but also affect cell function by stabilizing the miRNAs activities40. Ⅱ. circRNAs could form a regulatory pathway with other non-coding RNAs including small interfering RNA (siRNA) and long non-coding RNA (lncRNA). SiRNAs can infiltrate into 'RNA induced silencing complex' (RISC), leading to RNA interfere (RNAi), and then specifically inhibit the functions of circRNAs by binding with circRNAs41, 42. LncRNA or pseudogenes can inhibit the functions of miRNAs, and have synergistic effects with circRNAs 37, 43, 44. Transcription factors facilitate circRNA expressions by binding to promoters45. Ⅲ, circRNAs could form a regulatory pathway with proteins. The circRNAs can be the templates for mRNA translation, which impact on protein expression level directly, forming the circRNAs and proteins regulatory pathways27, 28. The regulatory pathways of circRNAs and proteins are found to be carried out in three ways. The first one is to regulate the translations of mRNAs indirectly by regulating the circRNA-miRNA pathways, thus affecting the synthesis of proteins46, 47 . CircRNA inhibits miRNA function and removes the inhibition of miRNA on mRNA, thus increasing protein content 48, 49. For example, in cells, circRNA_001569 regulates NR4A2 mRNA by acting with miR-14550. The second one is acting as RNA binding proteins (RBP) sponge, competitive binding with RBP, consequently influencing mRNA translation51. Both co-expressions of circRNA and RBP in the nucleus (such as circRNA MBL and MBL and ci-ankrd52 and POlII) and complexes formed by circRNAs and proteins in the cytoplasm are evidences of this molecular network17, 21, 52. Ⅳ. The above-mentioned three pattern could also function with each other which could compose of a network. A regulatory pattern that “circRNA-miRNA-mRNA” or “circRNA-miRNA-lncRNA” had been studied which were a ceRNA network4, 53. In summarized, circRNAs could form regulatory pathway with miRNAs, siRNAs, lncRNAs and proteins and then composed an interactive network.

CircRNAs involving in the regulations the biological behaviors of gastric cancer cells

Recent researches demonstrated that the expression level of circRNAs is closely related to the biological behavior of GC cells54, 55. A study regarding GC conducted by Li,J, et al showed that circ_104916 had tumor inhibition effect, correlated with the proliferation, invasion, migration and epithelial mesenchymal transition (EMT) of GC cells56. In comparison with normal gastric tissues and GES-1 cell lines, the expression levels of circ_104916 in GC tissues and five GC cell lines were down-regulated56. And further in vitro experiments elucidated that circ_104916 could inhibit the proliferation, invasion, migration and the EMT process of GC cells56. Similarly, Zhang,J et al. found that the expression of circLARP4 in GC tissues was down-regulated compared with normal gastric tissues. circLARP4 could relieve the mRNA LATS1 inhibition by inhibiting the miR-424 function, hence affecting the proliferation and invasion of GC cells57. In this study, researchers first discovered that miR-424 had LATS1 binding site, facilitating the proliferation and invasion of GC cells by inhibiting the expressions of LATS157. Through prediction of bioinformatics, data analysis of circRNA expression profiles and the verification of luciferase reporter assay and RNA immunoprecipitation (RIP), they came to conclusion that the circLARP4 can serve as a sponge for miR-42457. Further experiments were designed to explore the effects of circLARP4 on the biological behaviors of GC cells and found that overexpression of circLARP4 inhibited the proliferation and invasion of GC cells, while down-regulation of circLARP4 promoted these processes57. Although these studies focused on different circRNAs, they all demonstrated that the GC tissue differently expressed circRNAs were intimately related to the biological behaviors of GC cells and might play vital roles in the pathogenesis and development of GC58, 59. Thus far, still numerous circRNAs are unconfirmed, and more mechanisms concerning the impact of circRNAs on biological behaviors of GC cells remain to be explored. Association between circRNAs and gastric cancer cells biological behavior in previous studies is shown in Table 1.
Table 1

CircRNAs associated with gastric cancer

RoleCircRNAscircRNA IDGene SymbolChromosomeBest transcriptFunctionMechanismYearRef.
OncogenecircPVT1/PVT1chr8/proliferationas a sponge for members of the miR-125 family201777
hsa_circ_0047905hsa_circ_0047905SERPINB5chr18NM_002639proliferationpositively correlated with their parental gene mRNA201775
circNRIP1NRIP1chr21NM_003489proliferationas a sponge for members of the miR-149-5p to affect the201947
migrationexpression level of AKT1
invasion
circDLSThas_circ_0032627DLSTchr14NM_001933proliferationas a sponge for members of the miR-502-5p to activate201946
invasionthe NRAS/MEK1/ERK1/2 signaling
hsa_circ_0067997hsa_circ_0067997FNDC3Bchr3NM_022763invasiveregulating miR-515-5p/XIAP axis201948
circ-ERBB2////proliferationsponged miR-503 and miR-637201954
apoptosis
migration
invasion
circRNA_001569////apoptosissuppressing the expression of miR-145, which was mediated by NR4A2201950
circPDSS1////apoptosisregulating miR-186-5p and NEK2,201949
circ_DONSON/DONSONchr21/proliferationrecruiting the NURF complex to initiate SOX4 expression201955
migration
invasion
apoptosis
SuppressorcircRNA_100269/LPHN2chr1/proliferationthe target miRNA was miR-630201778
circ-104916////proliferationdownregulated E-cadherin,upregulated,N-cadherin, Vimentin and Slug201756
migration
invasion
metastasis
hsa_circ_0000096hsa_circ_0000096HIAT1chr1NM_033055proliferationregulating cyclin D1, CDK6, MMP-2 and MMP-9201774
migration
circLARP4/LARP4chr12/invasionsponging miR-424 and upregulating LATS1 gene201757
circ-ZFR////proliferationsponging miR-130a/miR-107 and regulating PTEN201825
apoptosis
hsa_circ_0001368hsa_circ_0001368KLHL24chr3NM_017644proliferationmiR-6506-5p/FOXO3 axis201958
invasion
circFAT1 (e2)hsa_circ_0001461FAT1chr4NM_005245proliferationregulating the miR-548g/RUNX1 axis in the cytoplasm and targeting YBX1 in the nucleus201959
migration
invasion

Correlation between circRNA expression and clinicopathological features of patients with gastric cancer

In recent years, as the circRNAs researches progressed, relationships between circRNAs and human diseases have gradually emerged. Through in-depth analyses and comparisons of circRNAs expression profiles in different diseases, it has become an indisputable fact that circRNAs can present different expression profiles in different diseases. Currently, many researches have listed out the expression profiles of circRNAs in GC60. Comparing the GC tissues with adjacent tissues through microarray technique, Sui,W et al. discovered 1285 differentially expressed circRNAs 61. Moreover, Dang,Y. et al's research reported the circRNAs expression profiles using five GC tissues and five matched non-cancer tissues with circRNA chip technique, and revealed that totally 713 circRNAs (191 up-regulated and 522 down-regulated) were differentially expressed62. In spite of the results of circRNAs expression profiles obtained by different experimental techniques were distinct, they indicated that masses of circRNAs expression levels changed during the development of GC63-65. A study based on the results of microarray screening and qRT-PCR assay reported that the expression of hsa_circ_0000190 in GC tissues was down-regulated compared with that in adjacent normal tissues66. To assess the diagnostic value of hsa_circ_0000190, they generated a receiver operating characteristic (ROC) curve, observing that areas under the curve (AUC) were 0.60 and 0.75 in plasma and tissue, respectively. Moreover, the AUC, sensitivity and specificity of the combined group (combining plasma hsa_circ_0000190 and tissue hsa_circ_0000190) were 0.775, 0.712 and 0.750, respectively66. Further analyzing the association of hsa_circ_0000190 expression levels in GC tissue and plasma with the clinicopathological features of 104 GC patients, we discovered that the hsa_circ_0000190 expression levels were not only related to tumor size, lymph node metastasis and CA19-9 level, but also significantly correlated with CEA level, distal metastasis and TNM stage66. Results indicated that higher hsa_circ_0000190 levels in tissue were observed in GC patients with large tumor diameter (d≥5), no lymph node metastasis, no distant metastasis, low TNM stage and CA19-9 negative, while CEA positive patients had a higher hsa_circ_0000190 levels in plasma66. Another research revealed that hsa_circ_0001895 was also correlated with clinicopathological features of GC patients67. By analyzing the relationships between the clinicopathological features of 96 GC patients and hsa_circ_0001895 expression level in GC tissues, Shao,Y et al, found that the expression level of hsa_circ_0001895 was high in patients with well differentiation, Borrmann grade III and IV, and GEA positive expression67. Furthermore, Lu,R et al concerned with hsa_circ_0006633, detecting its expression level in GC cell line, tissue and plasma through qRT-PCR method and discovered it could act as a tumor suppressor molecule68. In healthy tissues, the expression of hsa_circ_0006633 was significantly higher than that in gastritis and atypical hyperplasia tissues, and it was significantly higher in paracancerous tissues than in GC tissues. Concerning the relationships between the expression level of hsa_circ_0006633 and clinicopathological features in 96 patients with GC, they elucidated that patients without distant metastasis and CEA positive patients had statistically higher expression level of hsa_circ_000663368. It will contribute to identifying novel molecules involved in the GC development by analyzing the correlations of differentially expressed circRNAs with the clinicopathological features of patients with GC and helps us in better recognizing the progression of GC.

CircRNAs can be used as a marker for early diagnosis of gastric cancer

CircRNAs can potentially be biomarkers for clinical disease diagnosis due to their more stable structure and longer half-life than linear RNAs, better abundance and high specificity. Of note, circRNAs in extracellular fluid (such as saliva and plasma) released through EVs and cell lysis are also abundant and specific, making circRNAs potentially useful as non-invasive biomarkers for clinical disease diagnosis. For GC patients, circRNAs in their tissues and plasma are expected to be biomarkers for early diagnosis of GC 12, 69, 70. For hsa_circ_002059, researchers suggested that it was significantly down-regulated in GC tissues and was correlated with distant metastasis and TNM stages through detecting 96 pairs of GC tissues and their corresponding normal gastric tissues by using qRT-PCR method71. Moreover, as a diagnostic marker for GC, the AUC of hsa_circ_002059 was 0.73, and the sensitivity, specificity and cut-off value were 0.81, 0.62 and 12.9, respectively71. Another research performed by Zhao Q. et al used qRT-PCR method to observe the expression level of hsa_circ_0000181 and indicated that it was significantly down-regulated in GC tissues and plasma of GC patients than in paired normal tissues and healthy people72. Additionally, analyses on its diagnostic value showed that the hsa_circ_0000181 level in GC tissue and plasma could act respectively as invasive and non-invasive biomarker for diagnosing GC72. Observing the diagnostic ability of hsa_circ_0000181 in GC tissues and in plasma samples, we found that the specificity of tissue specimens was 0.852 which was significantly higher than that of plasma samples 0.206; the sensitivity of tissue specimens was 0.539 while sensitivity of plasma samples was 0.99072. Therefore, plasma circRNAs, as diagnostic biomarkers, have advantages over tissue circRNAs in its non-invasiveness and better diagnostic ability for early GC. In conclusion, the sensitivities of hsa_circ_002059 detected in both tissue samples and plasma samples meet the requirements of the diagnosis biomarker for GC71. CircRNAs have vast application prospect in non-invasive diagnosis and early diagnosis of GC. The diagnostic efficiency of circRNAs as a biomarker for gastric cancer is shown in Table 2.
Table 2

Diagnostic efficiency of circRNAs for gastric cancer

CircRNAsSampleExpressionAUCSeSpcut-offYearRef.
hsa_circ_0047905tissueup-regulation0.8500.7430.877/201775
hsa_circ_0138960tissueup-regulation0.6470.6770.645/
hsa_circRNA_7690-15tissueup-regulation0.6810.6790.613/
hsa_circ_102958tissueup-regulation0.740///201960
hsa_circ_002059tissueDown-regulation0.7300.8100.62012.900201571
hsa_circ_0000096tissueDown-regulation0.8200.8800.56012.900201774
hsa_circ_0001649tissueDown-regulation0.8340.7110.8160.227201711
hsa_circ_0001895tissueDown-regulation0.7920.6780.8579.530201767
hsa_circ_0014717tissueDown-regulation0.6960.5940.81312.140201710
hsa_circ_0003159tissueDown-regulation0.7500.8520.56512.310201769
hsa_circ_0006633tissueDown-regulation0.7410.6000.8108.170201768
hsa_circ_0000190tissueDown-regulation0.7500.7210.6836.830201766
hsa_circ_0000190plasmaDown-regulation0.6000.4140.8753.070
hsa_circ_0000181tissueDown-regulation0.7560.5390.8529.400201772
hsa_circ_0000181plasmaDown-regulation0.5820.9900.2067.270
hsa_circ_0000745plasmaDown-regulation0.6830.8550.450/201712
hsa_circ_0001017, hsa_circ_0061276plasmaDown-regulation0.9660.9550.957/201870
hsa_circ_0000467plasmaup-regulation0.7900.7050.648/201976

CircRNAs provide new specific targets for the treatment of gastric cancer

Recently, as digging deeper into the circRNAs, researchers have a heightened awareness of their functions. Up-regulated or down-regulated circRNAs may be novel specific therapeutic targets for GC with different phenotypes, invasion or metastasis ability, improving the survival rate of patients with GC. Firstly, circRNAs can regulate the malignant phenotype related signaling pathway of GC through some specific functions. Hence, regulating the level of circRNAs may steer GC cells into a better condition. CiRS-7, as the firstly discovered circRNA with miRNA sponge function represses the miR-7 function in GC tissues73. Up-regulated ciRS-7 regulates the PTEN/PI3K/AKT pathway by suppressing miR-7, consequently affecting the apoptosis and migration of GC cells73. In addition, down-regulated hsa_circ_0000096 in GC tissues can impact the proliferation and migration of GC cells by modulating cyclin D1, CDK6, MMP-2 and MMP-974. Inhibited hsa_circ_0000096 significantly suppress the proliferation and migration of GC cells74. Besides, inhibition of hsa_circ_0047905, hsa_circ_0138960 and hsa_circRNA7690-15 not only down-regulates the expressions of maternal genes, but also represses the proliferation and invasion of GC cells, discovered in another study on GC 75. Based on these reported findings, researchers suggest that the inhibited intracellular circRNAs result in suppressed proliferation and invasion abilities of GC cells, thus attaining a better phenotype of GC. This phenomenon can also be observed in animals. For instance, the growth rate of mice injected with miR-7 over-expressed tumor cells is lower than that of mice injected with ciRS-7 over-expressed tumor cells. The inhibition of hsa_circ_0000096 in nude mice can induce the decrease of Ki67 and VEGF. Secondly, EVs make it possible for circRNAs to be applied to targeted therapy of GC. As a membranous vesicle, EVs can encapsulate specific biomolecules, participating in intracellular communications. Current studies have elucidated that circRNAs can be wrapped by EVs. Like circRNAs in cells, circRNAs exist in homeostasis in exocrine under normal conditions. In diseased conditions, however, homeostasis in exocrine is off, as the balance of intracellular circRNAs shifts. By modifying the number of EVs and specific circRNA levels in EVs, the content of circRNAs in receptor cells can be regulated which restores the homeostasis of the intracellular circRNAs, amending the downstream signaling pathways, such as miRNAs, so that the biological behaviors of receptor cells can be improved. These circRNAs play various roles in different periods of GC development through specific pathways. Compared with traditional therapies, these therapies using tissue and developmental stage specific circRNAs as targets for drugs or drug treatments act on particular targets, obtaining a more targeted way, which can not only help prevent side effects but also conduct individualized treatment for the distinct conditions of individual disease.

Correlation between circRNAs expression levels and prognosis in patients with gastric cancer

Recent studies have demonstrated that circRNAs not only affect the proliferation abilities of GC cells through regulating signal pathways and are related to different phenotypes, but also have the ability to predict the relapse free survival and overall survival of patients76. At present, biomarkers circPVT1, circ_100269, etc have been discovered in GC tissues to be associated with GC prognosis. CircPVT1 encoded by PVT1 gene was up-regulated in GC tissues, and was illustrated to be a proliferative factor for GC in further cell experiments77. Analyzing the expression of circPVT1 in 187 GC patients and their 85 months follow-up results, researchers revealed that circPVT1 was an independent prognostic biomarker for the overall survival (OS) rate and disease-free survival (DFS) of patients with GC77. Another study indicated that circ_100269 was associated with GC cell proliferation78. In vitro cell experiment, expression of circ_100269 was found to be inversely correlated with miR-630 and a direct interaction exist between them according to the results of dual-luciferase assay78. What's more, overexpressed circRNA_100269 could repress cell proliferation78. In tissue experiment, circRNA_100269 was downregulated in GC tissues, meanwhile demonstrating a prominent predictive function for the overall survival of the patients 78. All these findings suggested that circPVT1 and circRNA_100269 might not only play roles in the treatments of GC, but also be prognostic biomarkers for GC. Correlation between circRNAs and the prognosis of gastric cancer is shown in Table 3.
Table 3

CircRNAs and gastric cancer prognosis

CircRNAsSampleExpressionNumber of casesSurvivalFollow-up (months)HR (95%CI)YearRef.
circPVT1tissueUp-regulation187OS830.600(0.400-0.880)201777
ciRS-7tissueUp-regulation102OS602.110(0.940-3.890)201873
ciRS-7tissueUp-regulation154OS602.630(1.230-5.550)
circRNA_100269tissueDown-regulation112OS500.600(0.350-1.020)201778
circLARP4tissueDown-regulation80OS1080.502(0.240-1.048)201757
circPVT1tissueUp-regulation187DFS850.490(0.330-0.720)201777

Conclusion

CircRNA, as a kind of tissue specific RNA with more stable structure than linear RNAs play vital roles in physiological processes, pathological processes and disease progression. This review summarized CircRNAs and its relationship with gastric cancer from multi-angle of view. Evidence-based results suggests that circRNAs are not only involved in the regulation of the biological behaviors of GC cells, such as proliferation, invasion, migration and EMT, but also related to the clinicopathological features of GC patients, such as tumor differentiation, TNM stage and metastasis. CircRNAs are also regarded as biomarkers for early diagnosis and prognosis of GC. CircRNAs participating in the development of GC have the potential as novel targets for the individualized treatment of GC. The molecular mechanism explaining the correlations between circRNAs and GC is a emerging field and further researches are in demand. Furthermore, as biomarkers for the diagnosis and prognosis of GC, it's of vital significance to further screen and verify circRNAs in tissues and plasma.
  78 in total

1.  Exon-intron circular RNAs regulate transcription in the nucleus.

Authors:  Zhaoyong Li; Chuan Huang; Chun Bao; Liang Chen; Mei Lin; Xiaolin Wang; Guolin Zhong; Bin Yu; Wanchen Hu; Limin Dai; Pengfei Zhu; Zhaoxia Chang; Qingfa Wu; Yi Zhao; Ya Jia; Ping Xu; Huijie Liu; Ge Shan
Journal:  Nat Struct Mol Biol       Date:  2015-02-09       Impact factor: 15.369

2.  Increased complexity of circRNA expression during species evolution.

Authors:  Rui Dong; Xu-Kai Ma; Ling-Ling Chen; Li Yang
Journal:  RNA Biol       Date:  2016-12-16       Impact factor: 4.652

3.  circRNA biogenesis competes with pre-mRNA splicing.

Authors:  Reut Ashwal-Fluss; Markus Meyer; Nagarjuna Reddy Pamudurti; Andranik Ivanov; Osnat Bartok; Mor Hanan; Naveh Evantal; Sebastian Memczak; Nikolaus Rajewsky; Sebastian Kadener
Journal:  Mol Cell       Date:  2014-09-18       Impact factor: 17.970

4.  Clinical values of circular RNA 0000181 in the screening of gastric cancer.

Authors:  Qianfu Zhao; Shijun Chen; Tianwen Li; Bingxiu Xiao; Xinjun Zhang
Journal:  J Clin Lab Anal       Date:  2017-09-22       Impact factor: 2.352

5.  A novel circular RNA, circFAT1(e2), inhibits gastric cancer progression by targeting miR-548g in the cytoplasm and interacting with YBX1 in the nucleus.

Authors:  Jian Fang; Han Hong; Xiaofeng Xue; Xinguo Zhu; Linhua Jiang; Mingde Qin; Hansi Liang; Ling Gao
Journal:  Cancer Lett       Date:  2018-11-09       Impact factor: 8.679

6.  Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types.

Authors:  Julia Salzman; Charles Gawad; Peter Lincoln Wang; Norman Lacayo; Patrick O Brown
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

Review 7.  A view of pre-mRNA splicing from RNase R resistant RNAs.

Authors:  Hitoshi Suzuki; Toshifumi Tsukahara
Journal:  Int J Mol Sci       Date:  2014-05-26       Impact factor: 5.923

8.  Efficient backsplicing produces translatable circular mRNAs.

Authors:  Yang Wang; Zefeng Wang
Journal:  RNA       Date:  2014-12-01       Impact factor: 4.942

9.  CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630.

Authors:  Yan Zhang; Hao Liu; Wende Li; Jiang Yu; Jin Li; Zhiyong Shen; Gentai Ye; Xiaolong Qi; Guoxin Li
Journal:  Aging (Albany NY)       Date:  2017-06-27       Impact factor: 5.682

10.  A novel regulatory network among LncRpa, CircRar1, MiR-671 and apoptotic genes promotes lead-induced neuronal cell apoptosis.

Authors:  Aruo Nan; Lijian Chen; Nan Zhang; Zhenzhong Liu; Ti Yang; Zhishan Wang; Chengfeng Yang; Yiguo Jiang
Journal:  Arch Toxicol       Date:  2016-09-07       Impact factor: 5.153

View more
  16 in total

Review 1.  CircRNAs: Insights into Gastric Cancer.

Authors:  Sanjana Rajgopal; Sherine Joanna Fredrick; Venkatachalam Deepa Parvathi
Journal:  Gastrointest Tumors       Date:  2021-07-16

2.  Circular RNA circNHSL1 Contributes to Gastric Cancer Progression Through the miR-149-5p/YWHAZ Axis.

Authors:  Chunying Hui; Lei Tian; Xinling He
Journal:  Cancer Manag Res       Date:  2020-08-12       Impact factor: 3.989

3.  Depletion of Circular RNA circ_CORO1C Suppresses Gastric Cancer Development by Modulating miR-138-5p/KLF12 Axis.

Authors:  Yongqiang Fan; Min Liu; Anquan Liu; Nailing Cui; Zhimei Chen; Qian Yang; Aihua Su
Journal:  Cancer Manag Res       Date:  2021-05-11       Impact factor: 3.989

4.  Knockdown circZNF131 Inhibits Cell Progression and Glycolysis in Gastric Cancer Through miR-186-5p/PFKFB2 Axis.

Authors:  Xingjie Shen; Xiaoyan Zhu; Peixin Hu; Tingting Ji; Ying Qin; Jingyu Zhu
Journal:  Biochem Genet       Date:  2022-01-21       Impact factor: 2.220

5.  Silencing of hsa_circ_0101145 reverses the epithelial-mesenchymal transition in hepatocellular carcinoma via regulation of the miR-548c-3p/LAMC2 axis.

Authors:  Jinglan Jin; Huan Liu; Meishan Jin; Wanyu Li; Hongqin Xu; Feng Wei
Journal:  Aging (Albany NY)       Date:  2020-06-18       Impact factor: 5.682

6.  CircR2Cancer: a manually curated database of associations between circRNAs and cancers.

Authors:  Wei Lan; Mingrui Zhu; Qingfeng Chen; Baoshan Chen; Jin Liu; Min Li; Yi-Ping Phoebe Chen
Journal:  Database (Oxford)       Date:  2020-01-01       Impact factor: 3.451

7.  ADAM10 expression in gastric adenocarcinoma: Results of a curative gastrectomy cohort.

Authors:  Huseyin Alakus; Mustafa Kaya; Hatice Ozer; Hatice Reyhan Egilmez; Kursat Karadayi
Journal:  Pak J Med Sci       Date:  2021 Mar-Apr       Impact factor: 1.088

8.  CircHECTD1 Regulates Cell Proliferation and Migration by the miR-320-5p/SLC2A1 Axis in Glioblastoma Multiform.

Authors:  Wen Li; Shanshan Wang; Boquan Shan; Xiang Cheng; Hui He; Jianbing Qin; Yi Tang; Heyan Zhao; Meiling Tian; Xinhua Zhang; Guohua Jin
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

Review 9.  Circular RNAs regulate cancer-related signaling pathways and serve as potential diagnostic biomarkers for human cancers.

Authors:  Pranavi Garlapati; Jinjie Ling; Paul J Chiao; Jie Fu
Journal:  Cancer Cell Int       Date:  2021-06-23       Impact factor: 5.722

10.  N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.

Authors:  Qianqing Wang; Xiangcui Guo; Li Li; Zhihui Gao; Xiaoke Su; Mei Ji; Juan Liu
Journal:  Cell Death Dis       Date:  2020-10-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.